Adenoviral transduction of EGFR into pregnancy-adapted uterine artery endothelial cells remaps growth factor induction of endothelial dysfunction

Abstract

During pregnancy, uterine vascular vasodilation is enhanced through adapted Ca2+ signaling, facilitated through increased endothelial connexin 43 (Cx43) gap junctional communication (GJC). In preeclampsia (PE), this adaptive response is missing. Of note, the angiogenic factor VEGF can also act via Src and ERK to close Cx43 gap junctions. While VEGFR2 is necessary for such closure, a role VEGFR1 is less clear. We reasoned if VEGFR2 is acting alone, then substituting another growth factor receptor with VEGFR2-like signaling should have the same effect. In uterine artery endothelial cells derived from pregnant sheep (P-UAEC), endogenous EGFR expression is very low. When we used adenovirus to raise EGFR, we also dose-dependently induced EGF-sensitive Cx43 phosphorylation mainly via ERK, and corresponding loss of Ca2+ bursts, but eliminated VEGF effects on phosphorylation of Cx43 or loss of Ca2+ bursting. This surprising observation suggests that while activated EGFR may indeed substitute for VEGFR2, it also sequesters a limited pool of effector molecules needed for VEGFR2 to phosphorylate Cx43. Thus, low endogenous EGFR expression in P-UAEC may be a necessary strategy to allow VEGFR-2 control of GJC, a first step in initiating angiogenesis in healthy pregnancy. Of further

The Involvement of Cell Adhesion Molecules, Tight Junctions, and Gap Junctions in Human Placentation

“…CX43 is also expressed in the decidual endothelium and promotes vasodilation of the endothelium. Phosphorylation of CX43 inhibits this process, as a result of a loss of Ca 2+ burst [153] which can trigger endothelial dysfunction and preeclampsia.…”

Extracellular Vesicles as Signaling Mediators and Disease Biomarkers across Biological Barriers

“…This miRNA participates in the EMT, vasculo/angiogenesis and cell migration, and could contribute to maternal endothelial dysfunction, a condition linked to eclampsia, a life-threatening emergency in pregnancy. This seems to be also the case for PLAP-positive trophoblastic EVs expressing EGFR [264].…”

Dissection of effect mechanisms of Kudiezi injection against myocardial ischemia based on virtual screening and systems pharmacology approach

“…In other words, the inhibit of JNKs would attenuate myocardial ischemic apoptosis [36]. Epidermal growth factor (EGF) is also known to activate Src and MAPK pathways [37]. Therefore, down-regulation of epidermal growth factor receptor (EGFR) and MAPK family might be bene cial in preventing and treating myocardial ischemia.…”